The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes.
W. N. William Junior
No relevant relationships to disclose
R. S. Weber
No relevant relationships to disclose
J. J. Lee
No relevant relationships to disclose
J. Myers
No relevant relationships to disclose
L. E. Ginsberg
No relevant relationships to disclose
A. K. El-Naggar
No relevant relationships to disclose
E. M. Sturgis
No relevant relationships to disclose
A. L. Sabichi
No relevant relationships to disclose
M. S. Kies
No relevant relationships to disclose
E. Y. Hanna
No relevant relationships to disclose
A. C. Hessel
No relevant relationships to disclose
C. Lu
No relevant relationships to disclose
S. Y. Lai
No relevant relationships to disclose
R. Ayuste
No relevant relationships to disclose
S. M. Lippman
No relevant relationships to disclose
E. S. Kim
No relevant relationships to disclose